Hp. Meng et al., Intravenous AMP 579, a novel adenosine A(1)/A(2a) receptor agonist, induces a delayed protection against myocardial infarction in minipig, EUR J PHARM, 387(1), 2000, pp. 101-105
The aim of the study was to probe if acute administration of [1S-[1a,2b,3b,
4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methylpropyl]amino]-3H-imidazo[4,5
-b] pyridin-3-yl] cyclopentane carboxamide (AMP 579) could provide a delaye
d protection against myocardial ischemia-reperfusion injury after 24 h. Ane
sthetized Yucatan minipigs were given an intravenous (i.v.) loading dose (3
mu g/kg) of AMP 579 in 3 min followed by a 68-min infusion (0.3 mu g/kg/mi
n) and were allowed to recover. After 24 h, the animals were subjected to a
n open-chest operation and the left anterior descending coronary artery was
occluded for 40 min, followed by 3 h of reperfusion. Results indicated tha
t there were no significant differences in hemodynamic parameters between v
ehicle- and drug-treated groups either during drug infusion or ischemia-rep
erfusion. Both groups had similar area at risk (24.9% for vehicle and 25.1%
for AMP 579-treated). However, the infarct size was 36.5% of area at risk
in vehicle group (n = 8) and 12.5% in AMP 579 group (n = 8), representing a
66% reduction of infarct size by AMP 579 (p = 0.011). This is the first re
port to demonstrate that in a large animal model, a hemodynamically silent,
single i.v. dose of an adenosine receptor agonist can result in a delayed
protection against myocardial infarction. (C) 2000 Elsevier Science B.V. Al
l rights reserved.